Device Trial Radar · NCT05786625
Bronchoscopic Microwave Ablation of Lung Tissue
Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
35
Actual
Start
May 4, 2023
Primary completion
Nov 26, 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- Creo Medical LimitedNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 27, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety and feasibility of the Creo Medical MicroBlate™ Flex AB1 instrument used with the AB1 electrosurgical system in patients undergoing bronchoscopic microwave ablation of peripheral lung nodules.
Conditions
- Lung Cancer
Interventions
AblationDevice
Bronchoscopy and microwave ablation of lung nodule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Performance (Efficacy) EndpointTime frame: Up to day 30 patient visit.
- Primary Safety EndpointTime frame: Up to 30 days after the ablation procedure.
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Amsterdam University Medical Centres, Location AMC, Meibergdreef 9
Amsterdam, Netherlands
Royal Brompton and Harefield NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.